KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2025)

Historic Gross Profit for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $70.5 million.

  • Adaptive Biotechnologies' Gross Profit rose 17238.06% to $70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.1 million, marking a year-over-year increase of 7473.21%. This contributed to the annual value of $94.2 million for FY2024, which is 1530.17% up from last year.
  • Adaptive Biotechnologies' Gross Profit amounted to $70.5 million in Q3 2025, which was up 17238.06% from $35.3 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Gross Profit registered a high of $70.5 million during Q3 2025, and its lowest value of -$16.2 million during Q2 2023.
  • Its 5-year average for Gross Profit is $22.0 million, with a median of $19.6 million in 2024.
  • In the last 5 years, Adaptive Biotechnologies' Gross Profit tumbled by 18345.12% in 2023 and then skyrocketed by 24145.44% in 2024.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Gross Profit stood at $11.2 million in 2021, then surged by 180.24% to $31.5 million in 2022, then dropped by 24.15% to $23.9 million in 2023, then grew by 8.4% to $25.9 million in 2024, then skyrocketed by 172.38% to $70.5 million in 2025.
  • Its last three reported values are $70.5 million in Q3 2025, $35.3 million for Q2 2025, and $29.4 million during Q1 2025.